$8m to grow Estech's cardiac surgery sales
This article was originally published in Clinica
Executive Summary
Privately-held cardiac surgery device manufacturer Endoscopic Technologies, or Estech, has completed an $8m equity financing round led by NBGI Ventures. The funds will be used to further expand commercialisation of the Estech's products, which are used by the cardiothoracic surgeon to perform minimally-invasive valve repair and replacement, coronary bypass and radiofrequency-based cardiac ablation procedures. This recent funding, to which Estech's existing shareholders also contributed, is in addition to the $11.3m which the San Ramon, California-based company raised in September 2008.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.